Match!

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

Published on May 4, 2019in Inflammatory Bowel Diseases4.005
· DOI :10.1093/ibd/izy323
Brian G. Feagan95
Estimated H-index: 95
(UWO: University of Western Ontario),
Stefan Schreiber S150
Estimated H-index: 150
(CAU: University of Kiel)
+ 10 AuthorsSharon O'Byrne10
Estimated H-index: 10
(Takeda Pharmaceutical Company)
Abstract
  • References (26)
  • Citations (1)
📖 Papers frequently viewed together
3 Citations
3 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References26
Newest
#1Jean-Frederic Colombel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 129
#2Mary E. Keir (Genentech)H-Index: 11
Last. Timothy T. Lu (Genentech)H-Index: 4
view all 7 authors...
Objective Both endoscopy and histology may be included in the definition of mucosal healing in UC. This study aimed to establish the association between patient-reported outcomes, specifically symptom measures, and the presence of inflammation as measured by endoscopy and histology in UC. Design Using patient data from an observational multicentre study of UC (n=103), rectal bleeding (RB) and stool frequency (SF) symptom subscores of the Mayo Clinic Score (MCS) were compared with the endoscopic ...
36 CitationsSource
#1Siew C. Ng (CUHK: The Chinese University of Hong Kong)H-Index: 50
#2William Palo (Takeda Pharmaceutical Company)H-Index: 3
Last. Fatima Bhayat (Takeda Pharmaceutical Company)H-Index: 4
view all 5 authors...
Introduction The risk of opportunistic infections (OIs) in inflammatory bowel disease increases with the use of biologics compared with placebo (odds ratio [OR]: 1.90). 1 Vedolizumab (VDZ), a humanised monoclonal antibody, targets α 4 β 7 integrin and selectively blocks gut-specific lymphocyte trafficking. Gut selectivity may be associated with a lower risk of infection compared with anti-tumour necrosis factor-alpha (TNFα) agents, which cause systemic immunosuppression. We assessed the frequenc...
2 CitationsSource
#1Severine Vermeire (University of Cambridge)H-Index: 1
#2Edward V. Loftus (University of Cambridge)H-Index: 1
Last. Arpeat KaviyaH-Index: 4
view all 17 authors...
Introduction Vedolizumab (VDZ), a gut-selective humanised monoclonal antibody that targets α 4 β 7 integrin, is approved for moderately to severely active Crohn’s disease and ulcerative colitis (UC). The ongoing GEMINI open-label extension (OLE) trial is investigating the long-term safety of VDZ (NCT00790933). We report 5 year exploratory interim analyses of effectiveness and safety in patients (pts) with UC who completed GEMINI 1 and enrolled in GEMINI OLE. Method Pts who responded to VDZ induc...
4 CitationsSource
#1Adrian D. VickersH-Index: 1
#2Claire AinsworthH-Index: 2
Last. Michael Smyth (Takeda Pharmaceutical Company)H-Index: 7
view all 7 authors...
Background Biological therapies are increasingly used to treat ulcerative colitis (UC). Aim To compare the efficacy of biologics in adults with moderately-to-severely active UC, stratified by prior exposure to anti-tumour necrosis factor (anti-TNF) therapy. Methods A systematic literature review was undertaken to identify studies of biologics approved for UC. Network meta-analysis was conducted for endpoints at induction and maintenance. Results Seven studies were included in the meta-analysis o...
31 CitationsSource
Introduction Crohn's disease and ulcerative colitis are lifelong illnesses which have a significant impact on quality of life and personal burden through a reduction in the ability to work, sick leave and restrictions of leisure time. The aim of this study was to conduct a systematic review of the indirect costs of Crohn's disease and ulcerative colitis.
15 CitationsSource
#1Tiffany TaftH-Index: 13
#2Laurie Keefer (NU: Northwestern University)H-Index: 31
Chronic illness stigma is a global public health issue. Most widely studied in HIV/AIDS and mental illness, stigmatization of patients living with inflammatory bowel disease (IBD), chronic autoimmune conditions affecting the digestive tract, has garnered increasing attention in recent years. In this paper, we systematically review the scientific literature on stigma as it relates to IBD across its three domains: perception, internalization, and discrimination experiences. We aim to document the ...
21 CitationsSource
Tumor necrosis factor-α (TNFα) antagonists have advanced the management of inflammatory bowel diseases patients leading to an improvement of patient's quality of life with the reduction of number of surgeries and hospitalizations. Despite these advances, many patients do not respond to the induction therapy (primary non-response—PNR) or lose response during the treatment (secondary loss of response—LOR). In this paper we will provide an overview of the definition, epidemiology and risk factors f...
110 CitationsSource
#2WilliamJSandborn (UCSD: University of California, San Diego)H-Index: 142
Last. Jean-Frederic Colombel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 129
view all 38 authors...
OBJECTIVES: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat-to-target" clinical management strategy using an evidence-based expert consensus process. METHODS: A Steering Committee of 28 IBD specialists developed recommendations based on a systematic literature rev...
472 CitationsSource
#1Alexis RamosH-Index: 2
#2Xavier Calvet (Autonomous University of Barcelona)H-Index: 50
Last. Fernando Gomollón (ISCIII: Carlos III Health Institute)H-Index: 14
view all 9 authors...
Background and aims: Data on the prevalence of work disability in patients with inflammatory bowel disease (IBD) are heterogeneous. As most studies have been performed in selected, often severe, IBD patients, the true prevalence of disability in the community remains controversial. The aim of this cross-sectional study was to evaluate the prevalence and severity of disability and its predictive factors in a community-based IBD population. Patients and methods: Patients recorded in the community-...
14 CitationsSource
#1Mahshid Tabatabaeian (IUMS: Isfahan University of Medical Sciences)H-Index: 1
#2Hamid Afshar (IUMS: Isfahan University of Medical Sciences)H-Index: 18
Last. Peyman Adibi (IUMS: Isfahan University of Medical Sciences)H-Index: 22
view all 9 authors...
Background: Psychological profile of inflammatory bowel disease patients is not well studied in Iran. We investigated the psychological status of Iranian patients with ulcerative colitis (UC) and its relationship with disease activity and quality of life (QOL). Materials and Methods: A cross-sectional study was conducted on adult UC patients. The Lichtiger Colitis Activity Index, Hospital Anxiety and Depression Scale, General Health Questionnaire-12, and WHOQOL-BREF, were completed by the patien...
9 CitationsSource
Cited By1
Newest
#1Lorenzo Bertani (UniPi: University of Pisa)H-Index: 8
#2Laura Baglietto (UniPi: University of Pisa)H-Index: 54
Last. Ersilia Lucenteforte (UniPi: University of Pisa)H-Index: 25
view all 15 authors...
AIMS: Vedolizumab (VDZ) prevents migration of activated leucocytes into inflamed mucosa. This study aimed to assess the patterns of serum cytokines in ulcerative colitis (UC) patients at baseline and during VDZ treatment, and to investigate their association with mucosal healing and clinical remission. METHODS: We enrolled consecutive UC patients eligible for treatment with VDZ. A panel of serum cytokines were measured by fluorescence assay at weeks 0, 6 and 22. Colonoscopy was performed at base...
2 CitationsSource
#1Ferdinando D’Amico (University of Lorraine)H-Index: 1
#2Silvio Danese (Humanitas University)H-Index: 25
Last. Laurent Peyrin-Biroulet (University of Lorraine)H-Index: 59
view all 3 authors...
AbstractIntroduction: Vedolizumab is a monoclonal antibody that selectively blocks α4β7 integrin and has already been approved for use in patients with moderate-to- severe ulcerative colitis both a...
Source
#2Gionata Fiorino (Humanitas University)H-Index: 30
Last. Silvio Danese (Humanitas University)H-Index: 63
view all 4 authors...
Source